Health Technology · Pharmaceuticals: Major · NSE: VIVIMEDLAB · data 2026-10-09

Vivimed Labs Limited

Health check: Weak (0.4/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹7.25

Market cap

₹56 cr

P/E

—

P/B

—

ROE

—

ROCE

-43.6%

Debt / equity

—

Dividend yield

0.00%

1-year return

38.1%

52-week high

₹29.4

52-week low

₹4.75

Operating margin

-255.0%

Growth

Revenue (last 12 months)	₹70 cr
Net profit (last 12 months)	₹-176 cr
Sales growth, 3 years (yearly)	-27.9%
Profit growth, 3 years (yearly)	—

Similar companies

Sunil Healthcare Ltd. (SUNLOC) · Zenith Drugs Ltd. (ZENITHDRUG) · Onyx Biotec Ltd. (ONYX) · Mangalam Drugs & Organics Ltd. (MANGALAM) · Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open VIVIMEDLAB in NSE Scanner →